{"nctId":"NCT04525885","briefTitle":"A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension","startDateStruct":{"date":"2019-05-17","type":"ACTUAL"},"conditions":["Chronic Cough"],"count":161,"armGroups":[{"label":"Gefapixant 45 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Gefapixant 45 mg twice daily (BID)","Drug: Gefapixant 45 mg BID"]},{"label":"Gefapixant 15 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Gefapixant 15 mg BID"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Gefapixant 45 mg twice daily (BID)","otherNames":["MK-7264"]},{"name":"Gefapixant 15 mg BID","otherNames":["MK-7264"]},{"name":"Placebo","otherNames":[]},{"name":"Gefapixant 45 mg BID","otherNames":["MK-7264"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chest radiograph or computed tomography scan of the thorax (within 5 years of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator\n* Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough\n* Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance\n* Provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires)\n\nExclusion Criteria:\n\n* Is a current smoker or has given up smoking within 12 months of Screening, or is a former smoker with greater than 20 pack-years\n* Has a history of respiratory tract infection or recent clinically significant change in pulmonary status\n* Has a history of chronic bronchitis\n* Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an ACEI within 3 months of Screening\n* Has an estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73 m\\^2 at Screening OR an eGFR ≥30 mL/min/1.73 m\\^2 and \\<50 mL/min/1.73 m\\^2 at Screening with unstable renal function\n* Has a history of malignancy \\<=5 years\n* Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence\n* Has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs\n* Has a known allergy/sensitivity or contraindication to gefapixant\n* Has donated or lost \\>=1 unit of blood within 8 weeks prior to the first dose of gefapixant\n* Has previously received gefapixant or is currently participating in or has participated in an interventional clinical study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24","description":"24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A longitudinal analysis of covariance (ANCOVA) model was applied to log-transformed cough data to determine geometric mean (GM) 24-hour coughs per hour at baseline and week 24. The GMR (Week 24 GM 24-hour coughs per hour divided by Baseline GM 24-hour coughs per hour) is reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null},{"groupId":"OG001","value":"0.51","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up","description":"Assessment of participants who have at least one AE during the main study period (24 weeks), the treatment extension period (28 weeks), and during 2 weeks of follow-up by telephone.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Treatment Due to an AE","description":"Assessment of participants who stop study treatment due to an AE during the main study period (24 weeks) or the treatment extension period (28 weeks).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline","description":"Awake coughs per hour was defined as the average hourly cough frequency while the participant is awake, based on a 24-hour interval of sound recordings using a digital recording device (cough monitor). ANCOVA model was applied to log-transformed cough data to determine GM of awake coughs per hour at baseline and week 24. The GMR (Week 24 GM awake coughs per hour divided by Baseline GM awake coughs per hour) is reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"0.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥1.3-point Increase From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24","description":"The 19-item LCQ assessed the impact of chronic cough in three health-related quality of life (HRQoL) domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21. Higher scores indicate better HRQoL. A clinically meaningful improvement from baseline in HRQoL was defined as ≥1.3-point increase in the LCQ total score at Week 24. The percentage of participants (logistic regression model-based) with a ≥1.3-point increase in the LCQ total score at Week 24 is presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥30% Reduction From Baseline in 24-hour Coughs Per Hour at Week 24","description":"24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A clinically meaningful improvement from baseline is defined as a ≥30% reduction in 24-hour coughs per hour at week 24. The percentage of participants (logistic regression model-based) with a ≥30% reduction from baseline in 24-hour coughs per hour at Week 24 (≥30% reduction from baseline) is presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"50.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥1.3-point Reduction From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24","description":"The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≥1.3 point reduction from baseline in CSD at Week 24 is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥2.7-point Reduction From Baseline of Mean Weekly CSD Total Score at Week 24","description":"The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≥2.7 point reduction from baseline in CSD at Week 24 is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"37.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥30 mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24","description":"The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 (\"No Cough\") to 100 (\"Extremely Severe Cough\"). Mean weekly VAS score was defined as the average of the VAS scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≥30mm reduction from baseline in cough severity VAS score at Week 24 is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"24.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":67},"commonTop":["Upper respiratory tract infection","Cough","Crystal urine present","Dysgeusia","Pharyngitis"]}}}